Detalhe da pesquisa
1.
Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study.
Am J Obstet Gynecol
; 228(4): 443.e1-443.e10, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36427596
2.
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883).
J Med Genet
; 59(3): 248-252, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33273034
3.
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Gynecol Oncol
; 164(2): 254-264, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34952708
4.
The correlation between transperineal ultrasound assessment of the levator ani muscle and postpartum urinary incontinence.
Neurourol Urodyn
; 40(7): 1786-1795, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34245601
5.
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(5): 699-709, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305099
6.
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
J Med Genet
; 56(9): 574-580, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30979843
7.
Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group.
Arch Gynecol Obstet
; 301(5): 1267-1274, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32277253
8.
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 19(9): 1247-1258, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30100379
9.
Impact of re-excision of residual adjacent vulvar intraepithelial neoplasia (VIN III) and histological tumour-free margin (hTFM) on survival in primary squamous cell carcinoma of vulva.
Arch Gynecol Obstet
; 298(5): 945-950, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30187190
10.
Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer.
Arch Gynecol Obstet
; 292(6): 1321-7, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25990476
11.
What is the evidence for lymphadenectomy in presumed early ovarian cancer?
Arch Gynecol Obstet
; 299(1): 1-5, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30374648
12.
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
J Clin Oncol
; 41(4): 893-902, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332161
13.
The correlation between levator ani co-activation and fetal head regression on maternal pushing at term.
J Matern Fetal Neonatal Med
; 35(25): 9654-9660, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35282757
14.
Histotype-specific analysis of acid ceramidase expression in ovarian cancer.
Virchows Arch
; 476(6): 855-862, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31897818
15.
Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
Neoplasia
; 21(4): 363-375, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30851646
16.
TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.
Pathol Oncol Res
; 24(2): 277-282, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28470574
17.
Catheter-related Complications of Subcutaneous Implantable Venous Access Devices in Breast Cancer Patients.
In Vivo
; 32(5): 1275-1281, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30150457
18.
Modern Myoma Treatment in the Last 20 Years: A Review of the Literature.
Biomed Res Int
; 2018: 4593875, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29789793
19.
Claudin-1 is linked to presence of implants and micropapillary pattern in serous borderline epithelial tumours of the ovary.
J Clin Pathol
; 71(12): 1060-1064, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30171086
20.
Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics.
Oncotarget
; 9(40): 25842-25859, 2018 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29899826